Marksans Pharma DuPont analysis

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	0.75×	0.75×	0.76×	0.74×	0.79×
	1.13×	1.12×	1.13×	1.10×	1.17×
	19.3%	17.0%	17.0%	17.6%	15.5%
	1.41×	1.41×	0.17×	0.89×	0.97×
	1.26×	1.26×	1.30×	1.29×	1.24×
	29.3%	25.4%	3.2%	16.5%	17.2%
	25.6%	25.6%	3.3%	18.0%	18.1%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

MARKSANS₹315.35

Marksans Pharma Ltd.

· Pharma & Health

₹ CrorePeersGRANULES METROPOLIS PARKHOSPS JLHL HCG RUBICON SHILPAMED SPARCMcap ₹14,290 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×	0.79	0.74	0.76	0.75	0.75
Interest Burden (Pretax/EBIT) ×	1.17	1.10	1.13	1.12	1.13
EBIT Margin %	15.52	17.65	16.98	17.02	19.34
Asset Turnover ×	0.97	0.89	0.17	1.41	1.41
Financial Leverage (Assets/Equity) ×	1.24	1.29	1.30	1.26	1.26
ROE (5-step product, year-end total equity) %	17.24	16.54	3.23	25.39	29.31
ROE (owners' profit / average owners' equity) %	18.07	17.98	3.31	25.56	25.56

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.